LONDON & NEW YORK--(BUSINESS WIRE)-- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company focused on advancing patient access to innovative treatments, has announced the successful achievement of the primary endpoint in its Phase 3 COMP005 trial. This trial is part of the ongoing evaluation of COMP360, a synthetic formulation of psilocybin, for use in treatment-resistant depression $(TRD.UK)$. The primary endpoint measured the difference in change from baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) scores between the active treatment group and the placebo group at week 6. Results showed a statistically significant reduction in symptom severity, with a mean difference of -3.6 and a p-value of <0.001. The Independent Data Safety Monitoring Board reported no unexpected safety findings. These preliminary results have not yet been reviewed by the U.S. Food and Drug Administration (FDA). Further data from the COMP005 trial are anticipated, along with findings from the second ongoing Phase 3 COMP006 trial, expected to be available in the second half of 2026.